Burkholderia cenocepacia: A new biocatalyst for efficient bioreduction of ezetimibe intermediate

Journal of Industrial Microbiology and Biotechnology

Volumn 36, Issue 11, 2009, Pages 1369-1374

  Singh, Amit ^a   Basit, Abdul ^a   Banerjee, Uttam C ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bioreduction; Burkholderia cenocepacia; Enzyme activity; Ezetmibe intermediate; Medium optimization

Indexed keywords

3 [5 (4 FLUOROPHENYL)HYDROXYPENTANOYL] 4 PHENYL 1,3 OXAZOLIDIN 2 ONE; ALCOHOL DERIVATIVE; BACTERIAL ENZYME; EZETIMIBE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BIOCATALYST; BIOREDUCTION; BURKHOLDERIA CENOCEPACIA; CATALYSIS; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; NONHUMAN; REACTION ANALYSIS; REDUCTION;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOSYNTHETIC PATHWAYS; BIOTRANSFORMATION; BURKHOLDERIA; CLUSTER ANALYSIS; COENZYMES; CULTURE MEDIA; DNA, BACTERIAL; DNA, RIBOSOMAL; HYDROGEN-ION CONCENTRATION; METALS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PHYLOGENY; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA; TEMPERATURE;

BURKHOLDERIA CENOCEPACIA;

EID: 70350236908     PISSN: 13675435     EISSN: 14765535     Source Type: Journal    
DOI: 10.1007/s10295-009-0622-z     Document Type: Article

References (11)

1. SW May 1999 Applications of oxidoreductases Curr Opin Biotechnol 10 370 375 10.1016/S0958-1669(99)80067-6 1:CAS:528:DyaK1MXlt1CgsLo%3D 10449319 (Pubitemid 29373952)
2. H Caner E Groner L Levy 2004 Trends in the development of chiral drugs Drug Discov Today 9 105 110 10.1016/S1359-6446(03)02904-0 1:CAS:528: DC%2BD2cXhtVOkurg%3D 15038394 (Pubitemid 38198306)
3. RN Patel 2008 Synthesis of chiral pharmaceutical intermediates by biocatalysis Coord Chem Rev 252 659 701 10.1016/j.ccr.2007.10.031 1:CAS:528:DC%2BD1cXislajsrk%3D
4. RC Neal PH Jones 2003 Lipid-lowering: can ezetimibe help close the treatment gap Clin J Med 70 777 783
5. S Yamagishi K Nakamura T Matsui T Sato M Takeuchi 2006 Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver Med Hypotheses 66 844 846 10.1016/j.mehy.2005.08.022 1:CAS:528:DC%2BD28XhtFWgsb4%3D 16188393 (Pubitemid 43181635)
6. HA Moutasim EC Nabil SS Ehab 2004 The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia Lipids Health Dis 3 22 28 10.1186/1476-511X-3-22 (Pubitemid 39532847)
7. Schering Corporation (2001) Process for the synthesis of azetidinones. US Patent 6,207,822
8. Schering Corporation (2000) Process for the synthesis of azetidinones. WO 00/34240
9. X Fu LM Timothy TK Thiruvengadam CH Tann S Dan 2003 Process for preparing ezetimibe intermediate by an acid enhanced chemo- and enantio-selective CBS catalyzed ketone reduction Tetrahedron Lett 44 801 804 10.1016/S0040-4039(02) 02700-4 1:CAS:528:DC%2BD3sXptFShsQ%3D%3D (Pubitemid 36153252)
10. B Bertrand S Durassier S Frein A Burgos 2007 Process for preparing ezetimibe intermediate by enantioselective CBS catalyzed ketone reduction with BH3-DEA prepared in situ Tetrahedron Lett 48 2123 2125 10.1016/j.tetlet.2007.01. 118 1:CAS:528:DC%2BD2sXit1yksbo%3D (Pubitemid 46275862)
11. Schering Corporation (1997) Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof. US Patent 5618707